Urine and serum concentrations of inhaled and oral terbutaline

TY - JOUR

T1 - Urine and serum concentrations of inhaled and oral terbutaline

AU - Elers, Jimmi

AU - Hostrup, Morten

AU - Pedersen, Lars

AU - Henninge, John

AU - Hemmersbach, Peter

AU - Dalhoff, Kim

AU - Backer, Vibeke

N1 - CURIS 2012 5200 129

PY - 2012

Y1 - 2012

N2 - We examined urine and serum concentrations after therapeutic use of single and repetitive doses of inhaled and supratherapeutic oral use of terbutaline. We compared the concentrations in 10 asthmatics and 10 healthy subjects in an open-label, cross-over study with 2mg inhaled and 10mg oral terbutaline on 2 study days. Further, 10 healthy subjects were administrated 1mg inhaled terbutaline in 4 repetive doses with total 4mg. Blood samples were collected at baseline and during 6h after the first inhalations. Urine samples were collected at baseline and during 12h after the first inhalations. Median (IQR) urine concentrations peaked in the period 0-4h after inhalation with Cmax 472 (324) ng/mL in asthmatics and 661 (517) ng/mL in healthy subjects, and 4-8h after oral use with Cmax 666 (877) ng/mL in asthmatic and 402 (663) ng/mL in healthy subjects. In conclusion we found no significant differences in urine and serum concentrations between asthmatic and healthy subjects. We compared urine and serum concentrations after therapeutic inhaled doses and supratherapeutic oral doses and observed significant statistical diffences in both groups but found it impossible to distinguish between therapeutic and prohibited use based on doping tests with urine and blood samples.

AB - We examined urine and serum concentrations after therapeutic use of single and repetitive doses of inhaled and supratherapeutic oral use of terbutaline. We compared the concentrations in 10 asthmatics and 10 healthy subjects in an open-label, cross-over study with 2mg inhaled and 10mg oral terbutaline on 2 study days. Further, 10 healthy subjects were administrated 1mg inhaled terbutaline in 4 repetive doses with total 4mg. Blood samples were collected at baseline and during 6h after the first inhalations. Urine samples were collected at baseline and during 12h after the first inhalations. Median (IQR) urine concentrations peaked in the period 0-4h after inhalation with Cmax 472 (324) ng/mL in asthmatics and 661 (517) ng/mL in healthy subjects, and 4-8h after oral use with Cmax 666 (877) ng/mL in asthmatic and 402 (663) ng/mL in healthy subjects. In conclusion we found no significant differences in urine and serum concentrations between asthmatic and healthy subjects. We compared urine and serum concentrations after therapeutic inhaled doses and supratherapeutic oral doses and observed significant statistical diffences in both groups but found it impossible to distinguish between therapeutic and prohibited use based on doping tests with urine and blood samples.

U2 - 10.1055/s-0032-1311590

DO - 10.1055/s-0032-1311590

M3 - Journal article

C2 - 22782385

SN - 0172-4622

VL - 33

SP - 1026

EP - 1033

JO - International Journal of Sports Medicine

JF - International Journal of Sports Medicine

IS - 12

ER -